Expert Opinion on Investigational Drugs, Volume 30, Issue 6 (2021)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 30, Issue 6 (2021)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Volume 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Editorial

Editorial
The challenges of combinatory immunotherapy for biliary tract cancer
Daniel Neureiter, Christian Mayr & Tobias Kiesslich
Pages: 591-594
Published online: 19 Apr 2021
First Page PreviewforThe challenges of combinatory immunotherapy for biliary tract cancer | Full Text | References | PDF (364.9 KB) | EPUB
  • 1093 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Drug Evaluation

Article
Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia
Akriti Gupta Jain, Chetasi Talati & Javier Pinilla-Ibarz
Pages: 595-601
Published online: 31 May 2021
AbstractforGalinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia | Full Text | References | PDF (698.4 KB) | EPUB
  • 244 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Dementia with Lewy bodies: emerging drug targets and therapeutics
Evans D. Pope, Laura Cordes, Jiong Shi, Zoltan Mari, Boris Decourt & Marwan Noel Sabbagh
Pages: 603-609
Published online: 26 Apr 2021
AbstractforDementia with Lewy bodies: emerging drug targets and therapeutics | Full Text | References | PDF (316 KB) | EPUB
  • 444 Views
  • 0 CrossRef citations
  • 0Altmetric
Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients
Julie M. Asare, Cara A. Rabik, Bradley Muller, Patrick A. Brown & Stacy Cooper
Pages: 611-620
Published online: 04 May 2021
AbstractforInvestigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients | Full Text | References | PDF (1.2 MB) | EPUB
  • 852 Views
  • 0 CrossRef citations
  • 0Altmetric
Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia
Stefano Molica, David Allsup, Valentina Gianfelici, Luciano Levato, Vincenzo Aiello, James Bailey & Aaron Polliack
Pages: 621-633
Published online: 15 May 2021
AbstractforCurrent and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia | Full Text | References | PDF (1.7 MB) | EPUB
  • 315 Views
  • 0 CrossRef citations
  • 0Altmetric
New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine
Alain Lescoat, John Varga, Marco Matucci-Cerinic & Dinesh Khanna
Pages: 635-652
Published online: 13 May 2021
AbstractforNew promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine | Full Text | References | PDF (5 MB) | EPUB
  • 714 Views
  • 1 CrossRef citations
  • 0Altmetric
Ewing sarcoma: investigational mono- and combination therapies in clinical trials
Jessica Gartrell & Carlos Rodriguez-Galindo
Pages: 653-663
Published online: 03 Jun 2021
AbstractforEwing sarcoma: investigational mono- and combination therapies in clinical trials | Full Text | References | PDF (395.9 KB) | EPUB
  • 363 Views
  • 0 CrossRef citations
  • 0Altmetric
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?
Talha Badar & Ehab Atallah
Pages: 665-673
Published online: 19 Apr 2021
AbstractforDo histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes? | Full Text | References | PDF (330.7 KB) | EPUB
  • 128 Views
  • 1 CrossRef citations
  • 0Altmetric

Explore articles